BetaCellsInDiabetes.org is a resource for physicians and healthcare professionals.
The information found here is not a substitute for medical advice, diagnosis or treatment.
ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments.
BetaCellsInDiabetes.org is a resource for physicians and healthcare professionals.
The information found here is not a substitute for medical advice, diagnosis or treatment.